GlobeNewswire by notified

Indberetning af ledende medarbejderes transaktioner med AGF A/S' aktier


Aarhus, den 27. oktober 2023

NASDAQ OMX Copenhagen A/S

Meddelelse nr. 26 /2023

Indberetning af ledende medarbejderes transaktionermed AGF A/S' aktier

I henhold til Markedsmisbrugsforordningen art. 19 oplyser AGF A/S at have modtaget
følgende meddelelse om erhvervelse af AGF A/S-aktier:

Navn:  Nørkjær Larsen Holding ApS
Årsag:Nørkjær Larsen Holding ApS ejes af Kim Larsen, der er bestyrelsesmedlem i AGF A/S
Udsteder:      AGF A/S
Handelsdato: Afsluttet pr. 25.10.2023
Marked:    NASDAQ OMX Copenhagen A/S
Antal:    1.070.388 stk.
Kursværdi:               674.344,44 DKK

Med venlig hilsen


Dan Holt Jessen

Vedhæftet fil

For at se dette indhold fra, så skal du give din accept på toppen af denne side.
For at se dette indhold fra, så skal du give din accept på toppen af denne side.

Information om GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg pressemeddelelser fra GlobeNewswire by notified

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra GlobeNewswire by notified

2024 Financial Calendar28.11.2023 14:56:32 CET | Press release

28 November 2023 News Release Pharma Equity Group 2024 Financial Calendar ​March 4Deadline for shareholder proposals - Annual General meeting​ ​March 20 ​Annual Report 2023​ April 16Annual General Meeting​ May 16Interim Report – for the three-month period ended March 31, 2024​ August 16Interim Report – for the six-month period ended June 30, 2024​ November 15Interim Report – for the nine-month period ended September 30, 2024 ​ Contact person – Investor Relations On the Company’s website further information and all published announcements can be found. Inquiries regarding relations with investors and the stock market can be directed to: Thomas Kaas Selsø, CEO, Phone: +45 4022 2114 E-mail: About Pharma Equity Group A/S Pharma Equity Group, a listed company on the Nasdaq Copenhagen stock exchange, is fully dedicated to advancing the medical projects of its subsidiary, Reponex Pharmaceuticals A/S. With an unwavering focus on healthc

Finanskalender for 202428.11.2023 14:56:32 CET | pressemeddelelse

28. november 2023 Pressemeddelelse Pharma Equity Group Finanskalender for 2024 4. martsFrist for aktionærforslag - Ordinær generalforsamling 20. marts Årsrapport 2023 16. aprilOrdinær generalforsamling 16. majDelårsrapport – for den tremåneders periode, der sluttede 31. marts 2024 16. augustDelårsrapport – for halvåret, der sluttede 30. juni 2024 15. novemberDelårsrapport – for den ni måneders periode, der sluttede 30. september 2024 Kontaktperson – Investor Relations På selskabets hjemmeside kan yderligere information og alle offentliggjorte meddelelser findes. Henvendelser vedrørende Investor Relations og aktiemarkedet kan rettes til: Thomas Kaas Selsø, CEO, Telefon: +45 4022 2114 E-mail: Om Pharma Equity Group A/S Pharma Equity Group, et børsnoteret selskab på Nasdaq Copenhagen, er fuldt dedikeret til at fremme datterselskabet Reponex Pharmaceuticals A/S' lægemiddelkandidater. Med et urokkeligt fokus på Healthcare er Pharma E

Alternus Energy Reports Third Quarter 2023 Financial Results28.11.2023 14:30:00 CET | Press release

DUBLIN, Ireland, Nov. 28, 2023 (GLOBE NEWSWIRE) -- International Renewable Independent Power Producer (IPP) Alternus Energy Group Plc (OSE: ALT) (the “Company” or “Alternus”) today announced unaudited U.S. GAAP financial results for the third quarter of 2023 under the US GAAP format. Q3 2023 Highlights Power production decreased by 5.4% YoY to 157 MWh due primarily to weather variances in Poland and the Netherlands.Revenue decreased by $1.9 million (15.3%) to $10.5 million compared to the same reporting period last year primarily because of lower electricity pricing in Poland and from lower irradiation levels due to seasonal weather conditions in Poland and the Netherlands.Gross profit increased by $0.5 million (6.4%) to $8.3 million resulting in gross margin of 79.0% as reduced revenues were offset by tightly controlled project operating costs.Selling and general expenses increased by $1 million (41%) YoY as the company grew personnel and infrastructure to drive development activities

Cellebrite Showcases Innovations in Digital Intelligence at Milipol 202328.11.2023 14:30:00 CET | Press release

Cellebrite demonstrates how agencies can increase productivity of digital investigations by making them smarter, more efficient and defensible TYSONS CORNER, Va. and PETAH TIKVA, Israel and PARIS, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Cellebrite DI Ltd. (Nasdaq: CLBT), a global leader in Digital Intelligence (DI) solutions for the public and private sectors, continued its commitment to accelerating justice around the globe with a leading presence at Milipol, the preeminent global law enforcement and homeland security event held November 14-17, 2023 in Paris. In addition to serving as one of the show’s sponsors, Cellebrite’s senior leadership, sales and service teams engaged with law enforcement professionals from more than 100 countries to discuss industry best practices and showcase recent innovations and emerging digital solutions. Highlights of Cellebrite’s show presence include: EMEA Senior Leadership convening with dozens of law enforcement professionals to discuss best practices and

Evaxion to Unveil Potentially Groundbreaking AI-Immunology™ Precision Cancer Vaccine Concept28.11.2023 14:27:00 CET | Press release

Proof of Concept – Evaxion’s AI-Immunology™ platform demonstrates success in designing precision cancer vaccines in hematological cancers by targeting a novel class of antigensBroad Applicability – The vaccine concept holds tremendous potential, offering broad applicability and promising benefits for patients with hematological malignancies COPENHAGEN, Denmark, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, proudly announces the presentation of its novel precision vaccine concept at the 65th American Society of Hematology (ASH) Annual Meeting, taking place in San Diego, California, from December 9-12, 2023. Selected for an Oral Presentation – Evaxion has been chosen for an oral presentation from a competitive pool of >5000 submitted abstracts. The presentation will unveil a breakthrough achievement using the Company’s proprietary AI target dis